Artificial Synthesis Of The Type III Secretion System Translocon. A New Approach To Vaccine Design
Funder
National Health and Medical Research Council
Funding Amount
$668,742.00
Summary
Today hospitals are plagued with bacterial infections that do not respond to antibiotics. The problem exists because although antibiotics are effective at killing bacteria, this paradoxically also helps the drug-resistant bacteria thrive. We will pioneer a completely new approach to vaccine design that allows us to construct a vaccine that protects us from bacterial infection without killing the bacteria. The vaccine should therefore be far less susceptible to drug resistance.
Structural And Functional Investigation Of Killer-Cell Immunoglobulin-like Receptors
Funder
National Health and Medical Research Council
Funding Amount
$546,966.00
Summary
Natural Killer (NK) cells are an important component of the immune response to cancer and infection. This project will define the molecular targets that are recognised by NK cells. This knowledge can then be used as a guide in the selection of bone marrow donors in the treatment of leukaemias as well as understanding how we fight infections.
Characterization And Inhibition Of Higher-order Assembly Signalling In Toll-like Receptor Pathways
Funder
National Health and Medical Research Council
Funding Amount
$711,995.00
Summary
The innate immune system is the first line of defence against pathogens. Inhibitors of innate immune pathways can be developed into therapeutic agents against a number of disorders including chronic inflammatory diseases, such as rheumatoid arthritis. We have discovered a new mechanisms of signaling by a set of key molecules in these pathways, through formation of large assemblies. We will characterize these assemblies and uncover ways to inhibit their formation.
A Structural, Chemical And Functional Investigation Into MAIT Cell Receptor Recognition
Funder
National Health and Medical Research Council
Funding Amount
$1,196,304.00
Summary
This project is focused on a type of T-cell, termed a MAIT cell, which is found abundantly in the lining of the gut. We are investigating how this MAIT cell is activated by riboflavin and folic acid metabolites. We are also examining how commonly prescribed drugs impact MAIT cells and how such activation may be linked to diseases, including inflammatory bowel disease.
Cytokine Structure And Mechanisms Of A Superagonist Antibody
Funder
National Health and Medical Research Council
Funding Amount
$349,590.00
Summary
Monoclonal antibodies are widely used in diagnosis and therapy due to their outstanding specificity and safety. The monoclonal antibodies recognizing cytokines with enhancing functions are an emerging class of novel reagents in immunotherapy. This project is to investigate how a newly indentified monoclonal antibody enhances the activity of a cytokine and use this immunostimulatory function to design new strategies for better vaccination and treatment for cancer and infection.
Harnessing Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$341,458.00
Summary
Critcial to the survival of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB) is its unique waxy (lipid)-rich cell wall. This proposal aims to target components of its cell wall to devlop novel therapeutic strategies. Specifically, the Australian-Singapore alliance will examine how the immune system "sees" lipid based antigens from M. tuberculosis, and then will ultimately use this information towards the devlopment of novel lipid-based vaccines.
An Investigation Into The Molecular Basis Of MAIT Cell Recognition Of Vitamin B Based Metabolites
Funder
National Health and Medical Research Council
Funding Amount
$883,762.00
Summary
Mucosal associated invariant T cells (MAIT cells) are an abundant T-cell population in humans, that is found mostly in the gastrointestinal mucosa. We have recently shown that MAIT cells can be activated by metabolites of vitamin B. This proposal will investigate how the MAIT cells "see" vitamin B metabolites. This research will pave the way for novel therapeutics that can modulate MAIT cell activity.
Development Of Stable Human Antibody Phage Display Libraries
Funder
National Health and Medical Research Council
Funding Amount
$539,644.00
Summary
Antibodies are blockbuster therapeutics for the treatment of cancer and inflammation. Unfortunately, they often display limited stability which greatly hinders development and production. This project focuses on the construction of large libraries of stable antibodies, thereby streamlining the development of new therapeutics.
Lipid Antigen Recognition By Diverse CD1-restricted T Cells
Funder
National Health and Medical Research Council
Funding Amount
$312,625.00
Summary
Natural Killer T (NKT) cells are a specialized T cell lineage that form a key part of the adaptive immune response required for protection against infection, allergy, cancer and autoimmune diseases. Different types of NKT cells exist, expressing distinct T cell receptors that recognize a large array of lipid antigens presented during disease conditions. Understanding the mechanisms involved in lipid recognition is crucial in deciphering how NKT cells can be manipulated for desired immune respons ....Natural Killer T (NKT) cells are a specialized T cell lineage that form a key part of the adaptive immune response required for protection against infection, allergy, cancer and autoimmune diseases. Different types of NKT cells exist, expressing distinct T cell receptors that recognize a large array of lipid antigens presented during disease conditions. Understanding the mechanisms involved in lipid recognition is crucial in deciphering how NKT cells can be manipulated for desired immune responses.Read moreRead less
A Molecular Investigation Into Lipid-reactive Immunity To Combat Mycobacterium Tuberculosis Infection
Funder
National Health and Medical Research Council
Funding Amount
$628,152.00
Summary
Tuberculosis (TB) infection currently causes ~1.5 million deaths annually. Due to new survival features acquired by the causative agent (Mycobacterium tuberculosis), traditional TB drugs and vaccines are becoming inefficient. Mycobacterium tuberculosis has a protective lipid-dense cell wall that is targeted by our immune system. We aim to understand the mechanisms of the lipid-mediated immune response to TB in order to develop more effective strategies to combat this disease.